.png)
The FDA has approved the use of immunotherapy (immune check point inhibitors) based on specific genetic biomarkers irrespective of the type of cancer or organ of origin eg.MSI-High tumors.
Precision oncology has revolutionized cancer therapy. Identifying cancers that might benefit from immunotherapy is possible through the genetic analysis of the tumors.
